Shots:
- VantAI has entered into a strategic research collaboration with Halda Therapeutics to advance the discovery & development of selective proximity-based therapies for cancer & immunology indications
- As per the deal, VantAI will receive over ~$1B incl. upfront, research support, development & commercial milestones as well as net sales-based tiered royalties
- VantAI will use its Neo-1 foundation model & NeoLink platform to discover target–effector pairs in oncology & immunology, accelerating Halda’s RIPTAC (regulated induced proximity targeting chimeras) pipeline with its unique “hold-and-kill” mechanism for precise, potent therapies
Ref: BusinessWire | Image: Halda Therapeutics and VantAI| Press Release
Related News:- Boehringer Ingelheim Joins Forces with Palatin to Develop Novel Therapies for Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
